In Europe, the combination of BV with CHP serves as a front-line therapy for previously untreated sALCL patients, while in the USA, this combination is additionally applied to other CD30-positive PTCL patients [9,19,20]. Here, TNFRSF8 is linked to mature T-cell and NK-cell non-Hodgkin lymphoma.